Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1163

1.

Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease.

Foell D, Wittkowski H, Ren Z, Turton J, Pang G, Daebritz J, Ehrchen J, Heidemann J, Borody T, Roth J, Clancy R.

J Pathol. 2008 Oct;216(2):183-92. doi: 10.1002/path.2394.

PMID:
18729068
2.

Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease.

Leach ST, Yang Z, Messina I, Song C, Geczy CL, Cunningham AM, Day AS.

Scand J Gastroenterol. 2007 Nov;42(11):1321-31.

PMID:
17852869
3.

Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease.

Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J.

Gut. 2003 Jun;52(6):847-53.

4.

S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules.

Foell D, Wittkowski H, Vogl T, Roth J.

J Leukoc Biol. 2007 Jan;81(1):28-37. Epub 2006 Aug 30. Review.

PMID:
16943388
5.

Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage.

Foell D, Wittkowski H, Roth J.

Gut. 2009 Jun;58(6):859-68. doi: 10.1136/gut.2008.170019. Epub 2009 Jan 9. Review.

PMID:
19136508
7.

Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.

Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D.

Gut. 2007 Dec;56(12):1706-13. Epub 2007 Aug 3.

8.

Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome.

Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michalsen A, Musial F, Dobos GJ.

Am J Gastroenterol. 2009 Feb;104(2):404-10. doi: 10.1038/ajg.2008.86. Epub 2009 Jan 20.

PMID:
19174795
9.

Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.

Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ.

Am J Gastroenterol. 2008 Jan;103(1):162-9. Epub 2007 Oct 4.

PMID:
17916108
10.
11.

Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease.

Gironella M, Iovanna JL, Sans M, Gil F, Peñalva M, Closa D, Miquel R, Piqué JM, Panés J.

Gut. 2005 Sep;54(9):1244-53. Epub 2005 May 3.

13.

Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease.

Griga T, Voigt E, Gretzer B, Brasch F, May B.

Hepatogastroenterology. 1999 Mar-Apr;46(26):920-3.

PMID:
10370639
14.

Proteomic analysis of the inflamed intestinal mucosa reveals distinctive immune response profiles in Crohn's disease and ulcerative colitis.

Berndt U, Bartsch S, Philipsen L, Danese S, Wiedenmann B, Dignass AU, Hämmerle M, Sturm A.

J Immunol. 2007 Jul 1;179(1):295-304.

15.

Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.

Sidler MA, Leach ST, Day AS.

Inflamm Bowel Dis. 2008 Mar;14(3):359-66.

PMID:
18050298
16.

Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.

Griga T, May B, Pfisterer O, Müller KM, Brasch F.

Hepatogastroenterology. 2002 Jan-Feb;49(43):116-23.

PMID:
11941933
17.

CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.

Vuckovic S, Florin TH, Khalil D, Zhang MF, Patel K, Hamilton I, Hart DN.

Am J Gastroenterol. 2001 Oct;96(10):2946-56.

PMID:
11693331
18.

Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.

Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Cosenza L, Staiano A, Troncone R.

Dig Liver Dis. 2008 Jul;40(7):547-53. doi: 10.1016/j.dld.2008.01.017. Epub 2008 Mar 20.

PMID:
18358796
19.

New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease.

Amati L, Passeri ME, Selicato F, Mastronardi ML, Penna A, Jirillo E, Covelli V.

Immunopharmacol Immunotoxicol. 2006;28(4):665-81.

PMID:
17190742

Supplemental Content

Support Center